Ionis Pharmaceuticals

An artists 3D rendering of cancerous blood cells among healthy red blood cells The cells fill the image and are of various
Biotech

Ono pays $280M upfront for Ionis' phase 2 blood cancer med

Japan's Ono Pharmaceutical is paying $280 million to acquire Ionis’ phase 2-stage antisense oligonucleotide for a rare type of blood cancer.
James Waldron Mar 12, 2025 6:30am
photo of a royal flush laid out on the poker table with chips scattered nearby

Arrowhead posts phase 3 data ahead of market clash with Ionis

Sep 3, 2024 9:27am
fence palisade wall defense fence gate fortress fort

Arrowhead RNAi med lowers triglycerides in phase 3

Jun 3, 2024 9:54am
oasis island desert palm treees surprise

Ionis reveals oasis for HAE patients as RNA med reduces attacks

May 31, 2024 10:40am
pipeline valve pipe flow water tap

Biogen walks away from Ionis-partnered ALS, Angelman prospects

May 16, 2024 9:24am
arrow archer target

Arrowhead on target in lipid disorder as it pursues Ionis

Apr 8, 2024 9:37am